Journal of Antimicrobial Chemotherapy (2003) 52, 303–305 DOI: 10.1093/jac/dkg318 Advance Access publication 1 July 2003 Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas Maria Scrascia1, Maria Forcillo1, Francesco Maimone1,2 and Carlo Pazzani1,2* 1Dipartimento di Anatomia Patologica e di Genetica, Sezione di Genetica, Università di Bari, Via G. Amendola 165/A, 70126 Bari; 2Interuniversity Research Centre for Sustainable Development, Università di Roma ‘La Sapienza’, Received 18 February 2003; returned 21 March 2003; revised 29 April 2003; accepted 6 May 2003Four hundred and eight clinical strains of Vibrio cholerae isolated from different geographical areas and with different antimicrobial resistance patterns were tested for susceptibility to rifaximin, a non-absorbable antibiotic active in vitro against Gram-negative bacteria. The MICs ranged from 0.5 to 4 mg/L for all strains. These values and the pharmacokinetic properties suggest rifaximin as an attractive antimicrobial agent for cholera.
Keywords: rifamycin derivative, antimicrobial activity, cholera
Introduction V. cholerae O139 isolated in India and two reference O1 strains of theclassical biotype were also included. Vibrio cholerae O1 El Tor biotype is the causative organism of the
Rectal swabs, stool samples, or both (in Cary-Blair transport medium)
current seventh cholera pandemic. In addition to O1 strains of the
were plated on thiosulphate-citrate-bile salts-sucrose (TCBS) (Oxoid,
El Tor biotype, strains of V. cholerae O139 and specific strains of
Milan, Italy) agar and incubated at 37°C for 18–24 h. Part of each speci-
V. cholerae O1 classical biotype are also responsible for cholera out-
men was enriched in alkaline peptone water pH 8.5 (Oxoid, Milan, Italy)
and then plated on TCBS agar. Well-isolated suspect colonies were picked
Antimicrobial agents in the treatment of cholera cases are often
to Kligler iron agar slants and tested for urease and oxidase production
recommended for reduction of symptomatology and vibrio excretion
(Oxoid, Milan, Italy). Isolates giving typical reactions were biochemic-
in the environment. The antimicrobials traditionally used have
ally characterized by the API 20E system with additional tests for Vibrio
been tetracycline, trimethoprim–sulfamethoxazole, erythromycin
spp. O-antigen groups were serologically identified by using commer-
cially available antisera. V. cholerae isolates were also tested by agglu-
Rifaximin, a rifamycin derivative, acts by binding irreversibly to
tination with chicken erythrocytes and polymyxin B susceptibility.
the β-subunit of the bacterial DNA-dependent RNA polymerase and
Original stock cultures of isolates were kept in 20% glycerol Luria-
inhibits RNA synthesis. Susceptibility testing of enterobacterial
Biotypes and genetic relationships of strains were identified by DNA-
pathogens associated with traveller’s diarrhoea has suggested that
based typing methods. Fingerprints of genomic DNA were obtained
rifaximin could be considered as a potential agent in the treatment of
using PCR to generate amplified polymorphic DNA (APD). The primers
intestinal bacterial infections.2 In this study, we investigated the in
were six oligonucleotides selected from enterobacterial repetitive con-
vitro activity of rifaximin against V. cholerae strains isolated from
sensus sequences,3 from V. cholerae repetitive DNA sequences,4 and
different outbreaks in different regions and in different years.
from the CTXφ phage genome of V. cholerae.5 Each strain was charac-terized by the combination of the six APD patterns. Combinations were
Materials and methods
compared and different APD clusters were identified to establish a refer-ence framework to assess clonal relatedness. Sources and characterization of V. cholerae strains
A total of 408 V. cholerae strains were analysed in this study (Table 1). Of
these, 359 V. cholerae O1 El Tor strains were isolated from clinical cases
The antibacterial susceptibility pattern of each isolate was determined
representative of outbreaks which occurred in Africa from 1985 to 1999,
by the disc diffusion method.6 The antimicrobial discs were used at the
12 El Tor strains were from outbreaks in Central and South America,
following concentrations: ampicillin (10 µg), chloramphenicol (30 µg),
and 32 strains from outbreaks in South Europe. Three clinical strains of
doxycycline (30 µg), kanamycin (30 µg), streptomycin (10 µg), spectino-
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
*Corresponding author. Fax: +39-080-544-3386; E-mail: pazzani@biologia.uniba.it.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The British Society for Antimicrobial Chemotherapy 2003; all rights reserved. M. Scrascia et al. Table 1. Clonal relatedness and antimicrobial resistance pattern of 408 V. cholerae strains of different geographical origins
AMP DOX KAN SMX SPT STR TET (57)/eastern AfricaAMP KAN SMX SPT STR TMP (2)/southern AfricaDOX SMX SPT STR TET TMP (6)/eastern and southern AfricaSMX SPT STR TMP (74)/eastern and southern AfricaSPT (89)/northern, eastern and southern Africa
AMP, ampicillin; DOX, doxycycline; KAN, kanamycin; SPT, spectinomycin; STR, streptomycin; TET, tetracycline; SMX, sulfamethoxazole; TMP,trimethoprim.
mycin (10 µg), tetracycline (30 µg), sulfamethoxazole (25 µg) and
Table 2. MIC s and MIC s (mg/L) of rifaximin and
trimethoprim (5 µg) (Oxoid, Milan, Italy). MICs of rifaximin and tetra-
tetracycline among V. cholerae O1 El Tor strainsa distributed
cycline (Sigma, Milan, Italy), were tested for each isolate according to
NCCLS guidelines7 with final concentrations ranging from 0.0125 to256 mg/L. Rifaximin was a gift from Alfa Wassermann SpA, Bologna,Italy (Batch i/2096c). Escherichia coli ATCC 25922 was used as a quality
Results and discussion
The clonal relatedness and the antimicrobial resistance patterns of the
408 V. cholerae O1 strains tested are shown in Table 1.
Genetic diversity was assessed by PCR fingerprinting with selected
primers generating amplified polymorphic genomic DNA. Clonal
aThe MIC range of RFX and TET for the three strains of V. cholerae
relationships were determined by comparison and analysis of com-
O139 and the two strains of V. cholerae O1 classical biotype was
binations of the amplified DNA patterns. On this basis, all strains
were clustered into 23 clones. The 359 strains isolated in Africa from1985 to 1999 consisted of 16 clones. The European and American
The distribution of the MICs of rifaximin and tetracycline for the
strains were classified in two clones, respectively, and the Indian
V. cholerae El Tor isolates by geographic area is given in Table 2.
MICs of tetracycline were determined for comparison between
Tests for antimicrobial susceptibility revealed six patterns within
rifaximin and a traditionally used antimicrobial. Tetracycline showed
the African strains. The large group of El Tor strains resistant to
lower activity for the African isolates (MIC = 64 mg/L) than for
ampicillin, sulfamethoxazole, spectinomycin, streptomycin, trimetho-
the European (MIC = 16 mg/L) and American (MIC = 2 mg/L)
prim (131 strains) and the group resistant to ampicillin, doxycycline,
isolates. No differences in the MIC s (2–4 mg/L) and MIC s
kanamycin, sulfamethoxazole, spectinomycin, streptomycin, tetra-
(2–4 mg/L) of rifaximin were observed among the three groups of O1
cycline (57 strains) isolated from East African countries in 1985,
1998 and 1999 belonged to four and two clones, respectively. Two
The MIC values of rifaximin for V. cholerae El Tor were far
susceptibility patterns were found in the European and Americanstrains, respectively.
lower than those found among other enteric bacterial pathogens
All strains were resistant to spectinomycin (100% of isolates) and
isolated from cases of traveller’s diarrhoea (MIC = 16 mg/L and
the vast majority were resistant to streptomycin (74%) and sulfa-
methoxazole (74%). Resistances to trimethoprim and ampicillin were
Rifaximin is a poorly absorbed antibiotic and in pharmacokinetic
present in 60% and 47% of all strains, respectively, corresponding
studies, high levels of rifaximin (up to 8000 µg/g) were detected in
to 81% and 63% of the multidrug-resistant isolates. A significant
faeces of patients and healthy volunteers after 3 days of a daily dosage
percentage of isolates were also resistant to tetracycline (22%), doxy-
of 800 mg.8 The MICs of rifaximin for all V. cholerae strains analysed
are well below the levels of faecal concentrations which rifaximin
Susceptibility of Vibrio cholerae to rifaximin
can reach in vivo. These findings indicate rifaximin as a candidate
4. Barker, A., Clark, C. A. & Manning, P. A. (1994). Identification of
antimicrobial agent to be tested in cholera patients.
VCR, a repeat sequence associated with a locus encoding a hemag- glutinin in Vibrio cholerae O1. Journal of Bacteriology 176, 5450–8. 5. Pearson, G. D. N., Woods, A., Chiang, S. L. et al. (1993). CTX Acknowledgements
genetic element encodes a site-specific recombination system and anintestinal colonization factor. Proceedings of the National Academy of
We thank Ida Luzzi (Istituto Superiore di Sanità, Rome, Italy) for
Sciences, USA 90, 3750–4.
providing isolates from Italy, Albania and America. This study was
6. Bauer, A. W., Kirby, W. M., Sherris, J. C. et al. (1966). Antibiotic
supported by a grant from Alfa Wassermann SpA and by grant IC18-
susceptibility testing by standardized single disc method. American Jour-
CT97-0231 (F.M.) from the European Commission under INCO-DC
nal of Clinical Pathology 45, 493–6. 7. National Committee for Clinical Laboratory Standards. (1998).
Performance Standards for Antimicrobial Susceptibility Testing: Approved
References
Standard M100-S8. NCCLS, Villanova, PA, USA. 8. Jiang, Z. D., Ke, S., Palazzini, E. et al. (2000). In vitro activity and 1. Faruque, S. M., Albert, M. J. & Mekalanos, J. J. (1998). Epidemi-
fecal concentration of rifaximin after oral administration. Antimicrobial
ology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiology
Agents and Chemotherapy 44, 2205–6.
and Molecular Biology Reviews 62, 1301–14. 9. Coppo, A., Colombo, M., Pazzani, C. et al. (1995). Vibrio cholerae 2. Gomi, H., Jiang, Z. D., Adachi, J. A. et al. (2001). In vitro antimicro-
in the Horn of Africa: epidemiology, plasmids, tetracycline resistance
bial susceptibility testing of bacterial enteropathogens causing traveler’s
gene amplification, and comparison between O1 and non-O1 strains.
diarrhea in four geographic regions. Antimicrobial Agents and Chemo-
American Journal of Tropical Medicine and Hygiene 53, 351–9.
therapy 45, 212–6. 10. Di Pierro, M., Lu, R., Uzzau, S. et al. (2001). Zonula occludens 3. Versalovic, J., Koeuth, T. & Lupski, J. R. (1991). Distribution of
toxin structure-function analysis. Identification of the fragment bio-
repetitive DNA sequences in eubacteria and applications to fingerprinting
logically active on tight junctions and of the zonulin receptor binding
of bacterial genomes. Nucleic Acids Research 19, 6823–31.
domain. Journal of Biological Chemistry 276, 19160–5.
M i wsp. Znaczenie zaka¿eñ grzybiczych i alergii Znaczenie zaka¿eñ grzybiczych i alergii na grzyby u chorychClinical relevance of fungal infection and allergy to mouldsMAREK NIEDOSZYTKO1,2/, MARTA CHE£MIÑSKA1/, MARTA GRUCHA£A-NIEDOSZYTKO3/, EWA JASSEM1/1/ Klinika Alergologii Akademii Medycznej w Gdañsku2/ Klinika Chorób Wewnêtrznych Endokrynologii i Zaburzeñ Hemostazy Akademii Me
SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING1.2. Relevant identified uses of the substance or mixture and uses advised againstPreservation of exterior timber surfaces. Applied by brush. See container for details. Not recommended for interior use on large surface areas or in confined spaces without suitable respiratory protection. 1.3. Details of the s